DAX+0,46 % EUR/USD-0,59 % Gold+0,44 % Öl (Brent)+0,96 %

Vical : Jetzt gehts richtig ab ! - 500 Beiträge pro Seite


ISIN: US10802T1051 | WKN: A2PRDX | Symbol: VCC2
1,510
13.12.19
Tradegate
-2,89 %
-0,045 EUR

Neuigkeiten zur Brickell Biotech Aktie


Beitrag schreiben

Begriffe und/oder Benutzer

 

Nachden Vical die letzten Tage bei steigenden Volumen und + 8% schon zündete ,steht jetzt
die Explosion bevor . Die heutigen Zahlen waren SEHR gut! Schlußkurs 24.66 $ . Nachbörslich im
BID 30 $ !!!!!

Vical Announces Third-Quarter 2000 Financial Results
SAN DIEGO, Nov 6, 2000 /PRNewswire via COMTEX/ -- Vical Incorporated (Nasdaq: VICL chart, msgs) announced
today its results of operations for the third quarter ended September 30, 2000. The company reported third-quarter 2000
revenues of $1.4 million compared with third-quarter 1999 revenues of $1.2 million. The net loss for the third quarter of 2000
was $1.9 million or $0.09 per share, compared with a net loss of $2.8 million or $0.18 per share for the same period in 1999.

For the nine months ended September 30, 2000, Vical`s net loss was $5.6 million or $0.29 per share, compared with a net
loss of $6.7 million or $0.42 per share for the first nine months of 1999. For both quarterly and year-to-date comparisons with
the prior year, increased interest income on the higher cash balances resulting from the company`s January 2000 stock offering
more than offset increased spending primarily associated with the company`s late-stage clinical trials. At September 30, 2000,
the company had cash, cash equivalents and marketable securities of $150.4 million, compared with $37.7 million at
December 31, 1999.

"Financial results for the third quarter and first nine months of 2000 were in line with our expectations," said Deirdre Y.
Gillespie, M.D., Vical`s Chief Operating Officer. "We continued to focus our resources on clinical development programs and
research activities directed toward expanding our product pipeline. Strategic investments provide the potential opportunities to
further leverage our technologies through independent and collaborative product development."

Recent Development

Researchers at Merck & Co., Inc. (NYSE: MRK chart, msgs) and Harvard University/Beth Israel Deaconess Medical Center
reported in the October 20, 2000, issue of Science successful testing in monkeys of an HIV vaccine under Merck`s license of
Vical`s patented naked DNA vaccine technology. The vaccine, given alone or in combination with a booster (interleukin-2),
protected the monkeys against a virulent strain of SHIV, a combination of simian (monkey) and human immunodeficiency virus.
Seven of the eight test monkeys receiving a placebo vaccine developed AIDS, and four died. All eight monkeys receiving the
booster vaccine, and two of four monkeys receiving the DNA vaccine alone, remained healthy. None of these 12 monkeys
died during the 140-day observation period.

Merck is now developing vaccines based on Vical`s naked DNA vaccine technology to prevent and treat HIV infections.
Merck is testing naked DNA vaccines for HIV in two human trials, one for uninfected volunteers and one for volunteers
already infected with HIV and receiving highly active anti-retroviral therapy. The human testing began in December 1999.

Vical Incorporated, The Naked DNA Company(TM), is focused on the development of pharmaceutical product candidates
based on its patented gene delivery technology. A number of therapeutic and vaccine product candidates are currently under
development for the prevention or treatment of cancer, infectious diseases and metabolic disorders by Vical and its
collaborative partners, including Merck & Co., Pfizer Inc., Aventis Pasteur, Aventis Pharma, Human Genome Sciences,
Centocor Inc., Merial and Boston Scientific Corporation. Allovectin-7(R), which uses a lipid-DNA complex to help the
immune system recognize and attack cancer cells, is in Phase II and Phase III testing in certain patients with metastatic
melanoma and in Phase II testing in patients with unresectable head and neck cancer. Leuvectin(TM), which uses a lipid-DNA
complex to stimulate an immune response against cancer cells, is in Phase II testing in patients with kidney cancer and prostate
cancer. Vaxid, a naked DNA vaccine to prevent relapse of B-cell lymphoma, is in Phase I/II testing. In collaboration with the
National Cancer Institute, a naked DNA vaccine to treat metastatic melanoma is in Phase I/II testing.

This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ
materially from those projected. Forward-looking statements include statements about the company`s focus, collaborative
partners, product candidates, and developmental status. Risks and uncertainties include whether any product candidates will be
shown to be safe and efficacious in clinical trials, the timing of clinical trials, whether Vical or its collaborative partners will seek
or gain approval to market any product candidates, and additional risks set forth in the company`s filings with the Securities
and Exchange Commission. These forward-looking statements represent the company`s judgment as of the date of this release.
The company disclaims, however, any intent or obligation to update these forward-looking statements.

For news releases and other information about the company, visit the Vical web site at www.vical.com.


VICAL INCORPORATED
STATEMENTS OF OPERATIONS
(in thousands, except share and per share amounts)

Three Months Ended Nine Months Ended
September 30, September 30,
2000 1999 2000 1999
(Unaudited) (Unaudited) (Unaudited) (Unaudited)
Revenues:
Contract revenue $706 $734 $1,609 $1,992
License/royalty
revenue 724 495 3,583 3,771
1,430 1,229 5,192 5,763
Expenses:
Research and
development 4,524 3,514 13,551 10,866
General and
administrative 1,263 1,067 3,903 3,202
5,787 4,581 17,454 14,068
Loss from
operations (4,357) (3,352) (12,262) (8,305)
Net interest
income 2,486 515 6,662 1,591

Net loss $(1,871) $(2,837) $(5,600) $(6,714)
Net loss per share
(Basic and
diluted) $(0.09) $(0.18) $(0.29) $(0.42)

Shares used in
per share
calculation 19,896,427 16,196,078 19,581,493 16,114,024


CONDENSED BALANCE SHEETS
(in thousands)

September 30, December 31,
2000 1999
(Unaudited)
Assets
Cash and cash equivalents $19,786 $11,149
Marketable securities 130,620 26,525
Other current assets 3,367 3,972
Total current assets 153,773 41,646
Investment, at cost 5,000 --
Property and equipment, net 3,290 1,886
Other assets 1,696 1,527
$163,759 $45,059

Liabilities and Stockholders` Equity
Current liabilities $5,533 $5,650
Long-term obligations 5,158 740
Stockholders` equity 153,068 38,669
$163,759 $45,059


Beitrag zu dieser Diskussion schreiben


Es handelt sich hier um eine ältere Diskussion, daher ist das Schreiben in dieser Diskussion nicht mehr möglich. Bitte eröffnen Sie hier eine neue Diskussion.